128 related articles for article (PubMed ID: 9531606)
1. The clinical significance of molecular response in indolent follicular lymphomas.
López-Guillermo A; Cabanillas F; McLaughlin P; Smith T; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Pugh W; Lee MS
Blood; 1998 Apr; 91(8):2955-60. PubMed ID: 9531606
[TBL] [Abstract][Full Text] [Related]
2. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
3. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
López-Guillermo A; Cabanillas F; McDonnell TI; McLaughlin P; Smith T; Pugh W; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Lee MS
Blood; 1999 May; 93(9):3081-7. PubMed ID: 10216105
[TBL] [Abstract][Full Text] [Related]
4. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.
López-Guillermo A; Cabanillas F; McLaughlin P; Smith T; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Pugh W; Lee MS
Ann Oncol; 2000; 11 Suppl 1():137-40. PubMed ID: 10707796
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
[TBL] [Abstract][Full Text] [Related]
6. Possible influence of clinical stage and type of treatment in the persistence of residual circulating t(14;18)-positive cells in follicular lymphoma patients.
Colleoni GW; Duarte LC; Kerbauy FR; Noguti MA; Felix RS; De Oliveira JS; Figueiredo MS; Alves AC
Leuk Lymphoma; 2004 Mar; 45(3):539-45. PubMed ID: 15160916
[TBL] [Abstract][Full Text] [Related]
7. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
Rambaldi A; Lazzari M; Manzoni C; Carlotti E; Arcaini L; Baccarani M; Barbui T; Bernasconi C; Dastoli G; Fuga G; Gamba E; Gargantini L; Gattei V; Lauria F; Lazzarino M; Mandelli F; Morra E; Pulsoni A; Ribersani M; Rossi-Ferrini PL; Rupolo M; Tura S; Zagonel V; Zaja F; Zinzani P; Reato G; Foa R
Blood; 2002 Feb; 99(3):856-62. PubMed ID: 11806987
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Santini G; Chisesi T; Nati S; Porcellini A; Zoli V; Rizzoli V; Zupo S; Marino G; Rubagotti A; Polacco A; Spriano M; Vimercati R; Congiu AM; Ravetti JL; Aversa S; Candela M; Patti C
Leuk Lymphoma; 2004 Jun; 45(6):1141-7. PubMed ID: 15359993
[TBL] [Abstract][Full Text] [Related]
10. Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas.
Soubeyran P; Hostein I; Debled M; Eghbali H; Soubeyran I; Bonichon F; Astier-Gin T; Hoerni B
Br J Cancer; 1999 Nov; 81(5):860-9. PubMed ID: 10555759
[TBL] [Abstract][Full Text] [Related]
11. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement.
Louissaint A; Ackerman AM; Dias-Santagata D; Ferry JA; Hochberg EP; Huang MS; Iafrate AJ; Lara DO; Pinkus GS; Salaverria I; Siddiquee Z; Siebert R; Weinstein HJ; Zukerberg LR; Harris NL; Hasserjian RP
Blood; 2012 Sep; 120(12):2395-404. PubMed ID: 22855608
[TBL] [Abstract][Full Text] [Related]
12. Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma.
Kornacker M; Kornacker B; Schmitt C; Leo E; Ho AD; Hensel M
Ann Hematol; 2009 Jan; 88(1):43-50. PubMed ID: 18636259
[TBL] [Abstract][Full Text] [Related]
13. The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21).
Ha CS; Tucker SL; Lee MS; McLaughlin P; Cabanillas F; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):727-32. PubMed ID: 11172955
[TBL] [Abstract][Full Text] [Related]
14. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
[TBL] [Abstract][Full Text] [Related]
15. Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report.
Ha CS; Cabanillas F; Lee MS; Besa PC; McLaughlin P; Cox JD
Clin Cancer Res; 1997 Feb; 3(2):215-9. PubMed ID: 9815675
[TBL] [Abstract][Full Text] [Related]
16. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
17. Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease?
Buchonnet G; Jardin F; Jean N; Bertrand P; Parmentier F; Tison S; Lepretre S; Contentin N; Lenain P; Stamatoullas-Bastard A; Tilly H; Bastard C
Leukemia; 2002 Sep; 16(9):1852-6. PubMed ID: 12200703
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.
Freedman AS; Gribben JG; Neuberg D; Mauch P; Soiffer RJ; Anderson KC; Pandite L; Robertson MJ; Kroon M; Ritz J; Nadler LM
Blood; 1996 Oct; 88(7):2780-6. PubMed ID: 8839876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
